Related Experiment Video
Updated: Sep 2, 2025

An In Vitro Model for Measuring Immune Responses to Malaria in the Context of HIV Co-infection
Published on: October 6, 2015
Impact of Epstein-Barr virus co-infection on natural acquired Plasmodium vivax antibody response
Michelle H F Dias1, Luiz F F Guimarães1, Matheus G Barcelos1
1Instituto René Rachou/FIOCRUZ Minas, Belo Horizonte, Minas Gerais, Brazil.
Insights
Epstein-Barr virus (EBV) co-infection may impact naturally acquired antibody responses to Plasmodium vivax malaria. Persistent EBV DNA in blood correlated with lower antibody levels to key malaria antigens, suggesting implications for immunity and vaccine development.
Area of Science:
- Immunology
- Infectious Diseases
- Tropical Medicine
Background:
- Epstein-Barr virus (EBV) establishes lifelong B-cell infections.
- EBV co-infection with Plasmodium falciparum is linked to Burkitt's Lymphoma.
- The impact of EBV on malaria immunity, particularly against Plasmodium vivax, is understudied.
Purpose of the Study:
- To investigate the influence of persistent Epstein-Barr virus (EBV) infection on naturally acquired antibody responses to Plasmodium vivax.
- To assess if EBV co-infection affects immune responses to malaria vaccine candidates.
Main Methods:
- Cross-sectional study with three surveys over 12 months in the Amazon.
- Compared malaria-exposed individuals with persistent EBV DNA (PersVDNA) versus no detectable EBV DNA (NegVDNA).
- Measured IgG antibodies to EBV antigens and P. vivax blood-stage antigens, including a novel DBPII immunogen (DEKnull-2).
Main Results:
- Individuals with persistent EBV DNA showed significantly higher IgG antibodies to EBV viral capsid antigen (VCA-p18).
- The PersVDNA group generally exhibited lower antibody levels to P. vivax antigens compared to the NegVDNA group.
- Significantly lower antibody responses were observed in the PersVDNA group to the DEKnull-2 immunogen, associated with neutralizing antibodies.
Conclusions:
- Persistent EBV DNA detection in semi-immune adults may impair long-term immune responses to P. vivax.
- This finding suggests EBV co-infection could influence the efficacy of malaria vaccines targeting blood-stage antigens.
- Further research is needed to understand the mechanisms by which EBV affects malaria immunity.
Background:
The simultaneous infection of Plasmodium falciparum and Epstein-Barr virus (EBV) could promote the development of the aggressive endemic Burkitt's Lymphoma (eBL) in children living in P. falciparum holoendemic areas. While it is well-established that eBL is not related to other human malaria parasites, the impact of EBV infection on the generation of human malaria immunity remains largely unexplored. Considering that this highly prevalent herpesvirus establishes a lifelong persistent infection on B-cells with possible influence on malaria immunity, we hypothesized that EBV co-infection could have impact on the naturally acquired antibody responses to P. vivax, the most widespread human malaria parasite.
Methodology/Principal Findings:
The study design involved three cross-sectional surveys at six-month intervals (baseline, 6 and 12 months) among long-term P. vivax exposed individuals living in the Amazon rainforest. The approach focused on a group of malaria-exposed individuals whose EBV-DNA (amplification of balf-5 gene) was persistently detected in the peripheral blood (PersVDNA, n = 27), and an age-matched malaria-exposed group whose EBV-DNA could never be detected during the follow-up (NegVDNA, n = 29). During the follow-up period, the serological detection of EBV antibodies to lytic/ latent viral antigens showed that IgG antibodies to viral capsid antigen (VCA-p18) were significantly different between groups (PersVDNA > NegVDNA). A panel of blood-stage P. vivax antigens covering a wide range of immunogenicity confirmed that in general PersVDNA group showed low levels of antibodies as compared with NegVDNA. Interestingly, more significant differences were observed to a novel DBPII immunogen, named DEKnull-2, which has been associated with long-term neutralizing antibody response. Differences between groups were less pronounced with blood-stage antigens (such as MSP1-19) whose levels can fluctuate according to malaria transmission.
Conclusions/Significance:
In a proof-of-concept study we provide evidence that a persistent detection of EBV-DNA in peripheral blood of adults in a P. vivax semi-immune population may impact the long-term immune response to major malaria vaccine candidates.
More Related Videos
09:57Measuring Naturally Acquired Phagocytosis-Inducing Antibodies to Plasmodium falciparum Parasites by a Flow Cytometry-Based Assay
Published on: August 6, 2020
07:39An In vitro Co-infection Model to Study Plasmodium falciparum-HIV-1 Interactions in Human Primary Monocyte-derived Immune Cells
Published on: August 15, 2012